Cerebrospinal fluid IL-6, TNF-α and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy

Neuropediatrics

Volumn 42, Issue 6, 2011, Pages 254-256

  Protas, P T ^a   Holownia, A ^a   Muszynska Roslan, K ^a   Wielgat, P ^a   Krawczuk Rybak, M ^a   Braszko, J J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

acute lymphoblastic leukaemia; chemotherapy; IL 6; MCP 1; neurotoxicity; TNF

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; MERCAPTOPURINE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHEMOKINE CCL2; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 83655165105     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0031-1295477     Document Type: Article

References (20)

1. Al-Gayyar M M, Eissa L A, Rabie A M et al. Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol: 2007; 59 409 417 (Pubitemid 47050906)
2. Allan S M, Rothwell N J. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci: 2003; 358 1669 1677 (Pubitemid 37298635)
3. Battisti V, Maders L D, Bagatini M D et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem: 2008; 41 511 518
4. Cole P D, Kamen B A. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev: 2006; 12 174 183 (Pubitemid 44646326)
5. de Lemos M L, Monfared S, Denyssevych T et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringers solution for intrathecal administration. J Oncol Pharm Pract: 2009; 15 45 52
6. Eisenkraft A, Keidan I, Bielorai B et al. MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia. Leuk Res: 2006; 30 1259 1261 (Pubitemid 44223731)
7. Ek T, Jarfelt M, Mellander L et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol: 2001; 37 459 464 (Pubitemid 33029641)
8. Iuvone L, Mariotti P, Colosimo C et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer: 2002; 95 2562 2570 (Pubitemid 35424043)
9. Kadan-Lottick N S, Brouwers P, Breiger D et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol: 2009; 27 5986 5992
10. Kingma A, van Dommelen R I, Mooyaart E L et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr: 2001; 139 413 420 (Pubitemid 32889519)
11. Mazor D, Abucoider A, Meyerstein N et al. Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: the impact of oxidative stress. Pediatr Blood Cancer: 2008; 51 613 615
12. Mazur B, Mertas A, Sota-Jakimczyk D et al. Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol Oncol: 2004; 22 27 34 (Pubitemid 38724549)
13. Mller-Hbenthal B, Azemar M, Lorenzen D et al. Tumor biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res: 2009; 29 4795 4805
14. Nathan P C, Wasilewski-Masker K, Janzen L A. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am: 2009; 23 1065 1082
15. Pui C H, Robison L L, Look A T. Acute lymphoblastic leukaemia. Lancet: 2008; 371 1030 1043 (Pubitemid 351389536)
16. Pui C H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program: 2006; 142 146
17. Schetter A J, Heegaard N H, Harris C C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis: 2010; 31 37 49
18. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol: 2009; 146 489 503
19. Shuper A, Stark B, Kornreich L et al. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J: 2002; 4 1050 1053
20. Vezmar S, Schsseler P, Becker A et al. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer: 2009; 52 26 32